Document Detail


Rate of serious adverse effects in a series of bevacizumab and ranibizumab injections.
MedLine Citation:
PMID:  22687306     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
OBJECTIVE: To compare the rate of serious ocular and systemic adverse effects of intravitreal bevacizumab and ranibizumab in the treatment of a variety of eye diseases.
DESIGN: Retrospective chart review.
PARTICIPANTS: Consecutive series of intravitreal injections of bevacizumab (n = 693) and ranibizumab (n = 891).
METHODS: Medical records of all patients receiving injections in the series were retrieved. We considered the rate of both serious ocular adverse effects (e.g., acute intraocular inflammation, infectious endophthalmitis, retinal detachment, vitreous hemorrhage) and of arterial thromboembolic events that occurred within 1 month of injection.
RESULTS: Subjects who received bevacizumab were 12 times more likely to develop severe intraocular inflammation following each injection than were those who received ranibizumab (OR = 11.71; 95% CI 1.5-93). The 1 case of acute intraocular inflammation following ranibizumab injection was mild and not associated with vision loss. No other serious ocular complications were noted. A trend was also noted toward an increased risk for arterial thromboembolic events in patients receiving bevacizumab, although the confidence interval was wide (OR = 4.26; 95% CI 0.44-41).
CONCLUSIONS: Significant concern still exists regarding the safety of off-label use of intravitreal bevacizumab. Patients receiving bevacizumab should be counselled regarding a possible increased risk for serious adverse events.
Authors:
Sanjay Sharma; Davin Johnson; Marwan Abouammoh; Simon Hollands; Ashley Brissette
Related Documents :
17336766 - The stable patient with schizophrenia--from antipsychotic effectiveness to adherence.
18204956 - Patients who are delayed from undergoing bariatric surgery do not have improved weight ...
16687026 - Gastrointestinal quality of life following laparoscopic adjustable gastric banding in a...
15826476 - One-anastomosis gastric bypass by laparoscopy: results of the first 209 patients.
21087536 - Perioperative antibiotic prophylaxis: improved compliance and impact on infection rates.
25201256 - A comparison of the incidence of complications following total hip arthroplasty in pati...
Publication Detail:
Type:  Comparative Study; Journal Article; Research Support, Non-U.S. Gov't    
Journal Detail:
Title:  Canadian journal of ophthalmology. Journal canadien d'ophtalmologie     Volume:  47     ISSN:  0008-4182     ISO Abbreviation:  Can. J. Ophthalmol.     Publication Date:  2012 Jun 
Date Detail:
Created Date:  2012-06-12     Completed Date:  2012-08-16     Revised Date:  2013-05-27    
Medline Journal Info:
Nlm Unique ID:  0045312     Medline TA:  Can J Ophthalmol     Country:  England    
Other Details:
Languages:  eng     Pagination:  275-9     Citation Subset:  IM    
Copyright Information:
Copyright © 2012 Canadian Ophthalmological Society. Published by Elsevier Inc. All rights reserved.
Affiliation:
Department of Ophthalmology, Queen's University, Kingston, Ont. sanjay_sharma60@hotmail.com
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Aged
Aged, 80 and over
Angiogenesis Inhibitors / adverse effects*
Antibodies, Monoclonal, Humanized / adverse effects*
Endophthalmitis / epidemiology*,  etiology
Female
Humans
Intravitreal Injections
Macular Edema / drug therapy
Male
Middle Aged
Retinal Detachment / epidemiology*,  etiology
Retinal Vein Occlusion / drug therapy
Retrospective Studies
Risk Factors
Thromboembolism / epidemiology*,  etiology
Vascular Endothelial Growth Factor A / antagonists & inhibitors
Visual Acuity
Vitreous Hemorrhage / epidemiology*,  etiology
Wet Macular Degeneration / drug therapy
Grant Support
ID/Acronym/Agency:
200101MSH-87845-60447//Canadian Institutes of Health Research
Chemical
Reg. No./Substance:
0/Angiogenesis Inhibitors; 0/Antibodies, Monoclonal, Humanized; 0/VEGFA protein, human; 0/Vascular Endothelial Growth Factor A; 0/ranibizumab; 2S9ZZM9Q9V/bevacizumab

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Three-year visual and anatomic results of administrating intravitreal bevacizumab in inflammatory oc...
Next Document:  Cannula detachment during cataract surgery: results of a survey.